(S) -10-Hydroxycamptothecin (Standard)

(S) -10-Hydroxycamptothecin (Standard) is the analytical standard of (S) -10-Hydroxycamptothecin. This product is intended for research and analytical applications. (S) -10-Hydroxycamptothecin (10-HCPT;10-Hydroxycamptothecin) is a DNA topoisomerase I inhibitor of isolated from the Chinese plant Camptotheca accuminata. (S) -10-Hydroxycamptothecin exhibits a remarkable apoptosis-inducing effect. (S) -10-Hydroxycamptothecin has the potential for hepatoma, gastric carcinoma, colon cancer and leukaemia treatment[1][2][3][4].

Product Specifications

CAS Number

[19685-09-7]

Product Name Alternative

10-HCPT (Standard) ; 10-Hydroxycamptothecin (Standard)

UNSPSC

12352005

Hazard Statement

H301-H340

Target

Apoptosis; Reference Standards; Topoisomerase

Type

Reference Standards

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Others

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/s-10-hydroxycamptothecin-standard.html

Smiles

O=C1[C@](O)(CC)C2=C(CO1)C(N3CC4=CC5=CC(O)=CC=C5N=C4C3=C2)=O

Molecular Formula

C20H16N2O5

Molecular Weight

364.35

Precautions

P264-P270-P280-P405-P501

References & Citations

[1]Min Liu, et al. Intracellular delivery of 10-hydroxycamptothecin with targeted nanostructured lipid carriers against multidrug resistance . Journal of Drug Targeting.|[2]Min Liu, et al. Intracellular delivery of 10-hydroxycamptothecin with targeted nanostructured lipid carriers against multidrug resistance. J Drug Target, Early Online: 1–8|[3]Yu P, et al. Synthesis and preliminary anticancer evaluation of 10-hydroxycamptothecin analogs. Biol Pharm Bull. 2012;35 (8) :1295-9.|[4]Zhang XW, et al. Differentiation-inducing action of 10-hydroxycamptothecin on human hepatoma Hep G2 cells. Acta Pharmacol Sin. 2000 Apr;21 (4) :364-8.|[5]Zhang XW, et al. Differential regulation of P53, c-Myc, Bcl-2, Bax and AFP protein expression, and caspase activity during 10-hydroxycamptothecin-induced apoptosis in Hep G2 cells. Anticancer Drugs. 2000 Oct;11 (9) :747-56.|[6]Liu M, et al. Intracellular delivery of 10-hydroxycamptothecin with targeted nanostructured lipid carriers against multidrug resistance. J Drug Target. 2016;24 (5) :433-40.